Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21592| Title: | New Advances in the Management of Cytomegalovirus in Allogeneic Haemopoietic Stem Cell Transplantation. | Austin Authors: | Yong, Michelle K;Gottlieb, David;Lindsay, Julian;Kok, Jen;Rawlinson, William;Slavin, Monica;Ritchie, David;Bajel, Ashish;Grigg, Andrew P | Affiliation: | Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney, New South Wales, Australia Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, New South Wales, Australia Pharmacy Department, Royal North Shore Hospital, New South Wales, Australia Department of Haematology and Bone Marrow Transplantation, Westmead Hospital, Sydney, New South Wales, Australia Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria, Australia NSW Health Pathology, Prince of Wales Hospital, New South Wales, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia |
Issue Date: | 12-Aug-2019 | Date: | 2020-03 | Publication information: | Internal Medicine Journal 2020; 50(3): 277-284 | Abstract: | Cytomegalovirus (CMV) viremia continues to be a frequent complication in the post haemopoietic stem cell transplant (HSCT) period despite a low incidence of CMV end-organ disease. A number of significant advances in the understanding and management of CMV infection have occurred in the last few years including improved diagnostics, monitoring of CMV immunity, availability of novel anti-CMV drugs, and emerging use of immunotherapies including CMV-specific T cell infusions. In addition to reviewing these advances we also explore some of the more practical prescribing issues of the older and newer CMV drugs including cost, toxicity and drug interactions to help clinicians navigate this new era of CMV management. This article is protected by copyright. All rights reserved. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/21592 | DOI: | 10.1111/imj.14462 | ORCID: | 0000-0002-8692-4145 0000-0002-4674-3403 |
Journal: | Internal Medicine Journal | PubMed URL: | 31403736 | Type: | Journal Article | Subjects: | CMV immune monitoring CMV-specific T cell therapy Cytomegalovirus haemopoietic stem cell transplantation letermovir maribavir |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.